ScreenerHero

ARDXArdelyx, Inc.

NAS · US · Healthcare · Biotechnology · ardelyx.com
3.890USD-3.47%Mkt Cap: 1.00B $P/E: —

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.00B $
Enterprise Value972.51M $
Revenue (TTM)450.89M $
Gross Profit367.78M $
Net Income (TTM)-61.60M $
Revenue/Share1.841 USD
Last Price3.890 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees489
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)15.48
PEG—
EV/EBITDA-30.29
EV/Revenue2.16
P/S2.23
P/B6.52
EPS (TTM)-0.22
EPS (Forward)0.25
52W Range
3.8601% of range8.400
52W High8.400 USD
52W Low3.860 USD
Profitability
Gross Margin90.29%
Oper. Margin-10.28%
EBITDA Margin-7.12%
Profit Margin-15.12%
ROE-36.90%
ROA-12.28%
Growth
Revenue Growth23.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-42.48M $
CapEx (TTM)1.49M $
FCF Margin4.54%
FCF Yield2.04%
Net Debt676.99K $
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity1.25
Current Ratio3.34
Quick Ratio2.89
Book Value/Sh0.5980 USD
Cash/Share1.131 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.90 USD
Upside (mean)+231.6%
Target Range8.000 USD – 18.00 USD
$8.000+231.6% to mean$18.00
# Analysts10
Ownership
Shares Out.258.19M
Float209.70M
Insiders3.23%
Institutions73.33%
Short Interest
Short Ratio8.7d
Short % Float10.76%
Short % Out.10.53%
Shares Short26.24M
Short (prev mo.)25.37M
Technical
SMA 505.086 (-23.5%)
SMA 2005.967 (-34.8%)
Beta0.73
S&P 52W Chg18.16%
Avg Vol (30d)3.88M
Avg Vol (10d)6.77M
Technical Indicators
RSI (14)23.4
MACD-0.3660
MACD Signal-0.3276
MACD Hist.-0.0383
BB Upper5.598 USD
BB Middle4.546 USD
BB Lower3.495 USD
BB Width46.26%
ATR (14)0.2091 USD
Vol Ratio (20d)0.64x